Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046955 · ClinicalTrials.gov registry record · Phase 4
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
A Phase 4 study of End Stage Renal Disease and Living Donors, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01046955 is a Phase 4 study of End Stage Renal Disease and Living Donors that has completed, run by University of Miami. The registered enrollment target is 38 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01046955, a Phase 4 study of End Stage Renal Disease and Living Donors, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to observe in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with the investigators standard treatment protocol of Zenapax® and maintenance immunosuppression.
Conditions Studied
Interventions
- DRUG Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
Study Locations (1)
Florida
- University of Miami Jackson Memorial Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01046955
The ClinicalTrials.gov registry entry for NCT01046955 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (95% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab is the first listed.
NCT01046955 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01046955 about?
NCT01046955 is a clinical study titled "Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation". The purpose of this study is to observe in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with the investigators standard treatment protocol of Zenapax® and maintenance immu...
What is the current status of trial NCT01046955?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2005-11. Estimated completion is 2008-12.
What conditions does trial NCT01046955 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Living Donors.
What interventions are being tested in trial NCT01046955?
The interventions under investigation include: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab (DRUG).
Who is sponsoring clinical trial NCT01046955?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01046955 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
COMPLETED · Phase 4
-
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
COMPLETED · Phase 4
-
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.